1 Min Read
May 17 (Reuters) - Neuralstem Inc
* Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.